Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04557280 · ClinicalTrials.gov registry record · Phase 1
A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects
A Phase 1 study, sponsored by Viatris Innovation.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04557280 is a Phase 1 study that has completed, run by Viatris Innovation. The registered enrollment target is 24 participants.
The verdict
NCT04557280, a Phase 1 study, has completed, sponsored by Viatris Innovation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The main purpose is to study the pharmacokinetics of selatogrel (ACT-246475) using different administration modes and formulations. The clinical pharmacology data will be used to support demonstration of bioequivalence and interchangeability of the different formulations.
Interventions
- COMBINATION_PRODUCT Selatogrel
- DRUG Selatogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-11-06 |
| Est. Completion | 2020-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04557280
The ClinicalTrials.gov registry entry for NCT04557280 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viatris Innovation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selatogrel is the first listed.
NCT04557280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04557280 about?
NCT04557280 is a clinical study titled "A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects". The main purpose is to study the pharmacokinetics of selatogrel (ACT-246475) using different administration modes and formulations. The clinical pharmacology data will be used to support demonstration of bioequivalence and interchangeability of the different formulations.
What is the current status of trial NCT04557280?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-11-06. Estimated completion is 2020-12-19.
What interventions are being tested in trial NCT04557280?
The interventions under investigation include: Selatogrel (COMBINATION_PRODUCT), Selatogrel (DRUG).
Who is sponsoring clinical trial NCT04557280?
This trial is sponsored by Viatris Innovation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.